Form 4: Corcept Therapeutics Director Daniel N. Swisher Jr. Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold the acquired shares under a pre-arranged 10b5-1 trading plan.
Summary
- On February 10, 2025, Daniel N. Swisher Jr., a director of Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $12.13 per share.
- Simultaneously, Swisher sold 2,200 shares of common stock at $68.08 per share.
- The transactions were executed under a pre-existing 10b5-1 trading plan.
- Following these transactions, Swisher directly owns 0 shares of Corcept Therapeutics common stock.
- Swisher also holds 6,200 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine insider transactions under a pre-arranged plan. There's no indication of positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives and directors to utilize 10b5-1 plans to manage their stock holdings and avoid accusations of insider trading. The sale price of $68.08 is a key data point for investors to consider in relation to the company's overall performance and stock valuation.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies.
- The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
- Comparing the transaction prices and volumes with those of peers like Exelixis or Halozyme Therapeutics can provide insights into market sentiment and valuation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a director.
- The impact is likely minimal as the transactions were conducted under a pre-arranged 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of stock option exercise and sale of shares. |
| 02/12/2025 | Date of signature on the Form 4 filing. |
| 05/24/2027 | Expiration date of the stock options. |
Keywords
Form 4, Corcept Therapeutics, Director, Stock Options, 10b5-1 Plan, Insider Trading, CORT, Swisher
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.